Mirati Therapeutics (BOVESPA:M2RT34) - Stock Price, News & Analysis

M2RT34 Stock Overview

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. More details

M2RT34 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 77.7% below our estimate of its fair value

Revenue is forecast to grow 42.24% per year

Risk Analysis

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Mirati Therapeutics, Inc. Competitors

Blau Farmacêutica

BOVESPA:BLAU3

R$2.7b

Biomm

BOVESPA:BIOM3

R$1.1b

Hypera

BOVESPA:HYPE3

R$12.7b

Bloomage BioTechnology

SHSE:688363

CN¥27.5b

Price History & Performance

Summary of all time highs, changes and price drops for Mirati Therapeutics
Historical stock prices
Current Share Price	US$19.46
52 Week High	US$21.64
52 Week Low	US$9.00
Beta	0.77
11 Month Change	1.35%
3 Month Change	4.96%
1 Year Change	28.96%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-54.84%

Recent updates

Shareholder Returns

	M2RT34	BR Biotechs	BR Market
7D	0.6%	1.2%	0.8%
1Y	29.0%	9.3%	-0.3%

Return vs Industry: M2RT34 exceeded the BR Biotechs industry which returned -1.1% over the past year.

Return vs Market: M2RT34 exceeded the BR Market which returned 9.3% over the past year.

Price Volatility

Is M2RT34's price volatile compared to industry and market?
M2RT34 volatility
M2RT34 Average Weekly Movement	1.7%
Biotechs Industry Average Movement	9.1%
Market Average Movement	4.5%
10% most volatile stocks in BR Market	8.2%
10% least volatile stocks in BR Market	2.3%

Stable Share Price: M2RT34 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine M2RT34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1995	587	Chuck Baum	www.mirati.com

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.

Mirati Therapeutics, Inc. Fundamentals Summary

How do Mirati Therapeutics's earnings and revenue compare to its market cap?
M2RT34 fundamental statistics
Market cap	R$20.53b
Earnings (TTM)	-R$3.62b
Revenue (TTM)	R$190.40m

107.8x

P/S Ratio

-5.7x

P/E Ratio

Is M2RT34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
M2RT34 income statement (TTM)
Revenue	US$38.19m
Cost of Revenue	US$510.48m
Gross Profit	-US$472.29m
Other Expenses	US$253.59m
Earnings	-US$725.88m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-10.35
Gross Margin	-1,236.66%
Net Profit Margin	-1,900.65%
Debt/Equity Ratio	0%

How did M2RT34 perform over the long term?

See historical performance and comparison

M2RT34 Stock Overview

Rewards

Risk Analysis

Mirati Therapeutics, Inc. Competitors

BOVESPA:BLAU3

R$2.7b

BOVESPA:BIOM3

R$1.1b

BOVESPA:HYPE3

R$12.7b

SHSE:688363

CN¥27.5b

Price History & Performance

Recent News & Updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Shareholder Returns

Price Volatility

About the Company

Mirati Therapeutics, Inc. Fundamentals Summary

107.8x

-5.7x

Earnings & Revenue